See more : National CineMedia, Inc. (NCMI) Income Statement Analysis – Financial Results
Complete financial analysis of Cartesian Therapeutics, Inc. (RNAC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cartesian Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- PT Tanah Laut Tbk (INDX.JK) Income Statement Analysis – Financial Results
- Income Asset Management Group Limited (IAM.AX) Income Statement Analysis – Financial Results
- Kew Media Group Inc. (KWWMF) Income Statement Analysis – Financial Results
- Athena Consumer Acquisition Corp. (ACAQ-UN) Income Statement Analysis – Financial Results
- AU Min Africa PTY, LTD. (GRYEF) Income Statement Analysis – Financial Results
Cartesian Therapeutics, Inc. (RNAC)
About Cartesian Therapeutics, Inc.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.00M | 110.78M | 85.08M | 16.60M | 6.68M | 903.00K | 207.00K | 8.08M | 6.01M | 3.04M |
| Cost of Revenue | 1.55M | 2.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 24.45M | 108.74M | 85.08M | 16.60M | 6.68M | 903.00K | 207.00K | 8.08M | 6.01M | 3.04M |
| Gross Profit Ratio | 94.03% | 98.16% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 71.84M | 72.38M | 68.74M | 54.51M | 42.74M | 47.69M | 45.17M | 29.70M | 22.98M | 10.49M |
| General & Administrative | 40.58M | 23.86M | 20.94M | 18.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.95M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 40.58M | 23.86M | 20.94M | 18.91M | 14.36M | 17.26M | 18.08M | 12.25M | 7.29M | 7.95M |
| Other Expenses | 0.00 | 330.00K | 15.00K | 89.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 110.87M | 96.24M | 89.67M | 73.42M | 57.11M | 64.95M | 63.24M | 41.95M | 30.27M | 18.44M |
| Cost & Expenses | 112.42M | 96.24M | 89.67M | 73.42M | 59.13M | 65.93M | 63.99M | 42.75M | 31.32M | 18.44M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 834.00K | 1.05M | 617.00K | 234.00K | 171.00K | 111.00K |
| Interest Expense | 2.83M | 3.03M | 2.84M | 1.56M | 1.52M | 1.49M | 1.21M | 1.25M | 948.00K | 552.00K |
| Depreciation & Amortization | 843.00K | 2.04M | 1.72M | 1.73M | 2.03M | 975.00K | 750.00K | 802.00K | 1.04M | 864.00K |
| EBITDA | -235.06M | 39.84M | -5.16M | -65.59M | -51.80M | -62.87M | -63.37M | -34.16M | -23.18M | -11.46M |
| EBITDA Ratio | -903.95% | 14.58% | -3.91% | -337.40% | -755.25% | -7,092.69% | -30,451.21% | -419.00% | -403.59% | -377.11% |
| Operating Income | -86.42M | 14.54M | -4.60M | -56.82M | -52.46M | -65.02M | -63.78M | -34.67M | -25.30M | -15.40M |
| Operating Income Ratio | -332.32% | 13.12% | -5.40% | -342.36% | -785.61% | -7,200.66% | -30,813.53% | -428.92% | -420.96% | -506.55% |
| Total Other Income/Expenses | -152.29M | 20.23M | -5.12M | -12.06M | -2.90M | -314.00K | -1.54M | -1.54M | 130.00K | 2.52M |
| Income Before Tax | -238.71M | 34.77M | -9.72M | -68.88M | -55.35M | -65.34M | -65.32M | -36.21M | -25.17M | -12.88M |
| Income Before Tax Ratio | -917.97% | 31.39% | -11.43% | -414.99% | -828.97% | -7,235.44% | -31,556.04% | -447.98% | -418.80% | -423.68% |
| Income Tax Expense | -19.00M | -609.00K | 15.97M | 1.65M | 1.86M | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -219.71M | 35.38M | -25.69M | -68.88M | -55.35M | -65.34M | -65.32M | -36.21M | -25.17M | -12.88M |
| Net Income Ratio | -844.91% | 31.94% | -30.19% | -414.99% | -828.97% | -7,235.44% | -31,556.04% | -447.98% | -418.80% | -423.68% |
| EPS | -42.49 | 7.33 | -6.74 | -20.42 | -36.46 | -87.55 | -95.94 | -103.52 | -40.50 | -38.17 |
| EPS Diluted | -42.49 | 2.98 | -6.74 | -20.42 | -36.46 | -87.55 | -95.94 | -103.52 | -40.50 | -38.17 |
| Weighted Avg Shares Out | 5.17M | 4.83M | 3.81M | 3.37M | 1.52M | 746.31K | 680.83K | 349.80K | 621.65K | 428.95K |
| Weighted Avg Shares Out (Dil) | 5.17M | 4.86M | 3.81M | 3.37M | 1.52M | 746.31K | 680.83K | 349.80K | 621.65K | 428.95K |
Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit
Cartesian Therapeutics: Uncertainty Remains
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting
Insider Buying Slows, but Not for 7 These Buyers
Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last?
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results
Source: https://incomestatements.info
Category: Stock Reports